
CATALIST-listed AOXIN Q&M Records 21% Growth In Revenue
CATALIST-listed AOXIN Q&M Records 21% Growth In Revenue For Full Year Ended 31 December 2021 - EBITDA grew 47% for 12 months ended 31 Dec 2021 - Proposed listing of 49%-owned Acumen Diagnostics on NASDAQ will enhance AOXIN's shareholder value ...